{"ok":true,"nota":{"id":"98d47784ca171fd5","slug":"una-vacuna-personalizada-con-arnm-redujo-mas-de-40-la-recaida-del-mela-98d477","titulo":"Una vacuna personalizada con ARNm redujo más de 40% la recaída del melanoma en un ensayo","resumen":"Un ensayo de fase 3 evaluó una vacuna de ARN mensajero adaptada al tumor de cada paciente con melanoma. Los resultados muestran una reducción de más de 40% en el riesgo de recurrencia.","fuente":"wired-sci","fuenteNombre":"WIRED · Ciencia","color":"#1d1a16","autor":"Fernanda González","url":"https://www.wired.com/story/new-melanoma-vaccine-reduces-risk-of-tumor-reoccurrence-by-over-40-percent/","imagen":"https://media.wired.com/photos/6adbb6236c5716eb12b3253b/master/pass/vacuna%20melanoma%202275195271.jpg","tema":"salud","subtemas":["melanoma","vacunas de arnm","oncología","medicina personalizada","ensayos clínicos"],"entidades":["WIRED","Moderna"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T11:30:00.000Z","indexTs":"2026-10-24T13:17:27.249Z","hash":"b178f49d31212c7b15b86d663a2244f084090a400210af7ca38faaf663208853","tsa":{"time":"Oct 24 13:18:25 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Un 40% menos de riesgo de que el melanoma vuelva es una mejora relevante para pacientes que ya fueron operados y viven con el miedo a la recaída. Lo novedoso es que la vacuna se diseña a medida del tumor de cada persona, algo que hasta hace poco parecía ciencia ficción. Para la salud pública argentina, la pregunta será cuánto tarda en llegar al sistema y a qué costo, porque el acceso va a depender de decisiones que todavía no están tomadas.","quienFirma":"Moderna y colaboradores (ensayo de fase 3)","confianza":"revisado","consulta":null},"sello":{"hash":"b178f49d31212c7b15b86d663a2244f084090a400210af7ca38faaf663208853","sello":"58902adcc4a2181c835792901d118b90705852732d2a52bbe6b342f066365ed7","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6580562,"aleatorio":"81c6ed6e3d97576b659df9c660c8e4d04e96777d755dce54e6ab2214029cd287","tiempo":"2026-10-24T13:18:00.000Z"},"nist":{"cadena":2,"pulso":1997474,"salida":"928C51653AF84355ABF10B2F9F2BEF68243B5A44EEAC367FBD4A8C48098F8B9265C61CC1C230C1A9FB49A7ECA995953528095FF68F95136E45CBC8C940F45237","tiempo":"2026-10-24T13:17:00.000Z"},"noAntes":"2026-10-24T13:18:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 13:18:25 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent","descripcion":"The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.","pubDate":"Sat, 24 Oct 2026 11:30:00 +0000","url":"https://www.wired.com/story/new-melanoma-vaccine-reduces-risk-of-tumor-reoccurrence-by-over-40-percent/"},"indexado":"2026-10-24T13:17:27.249Z"}}